Ahmed Aly (@a_aly_hussein) 's Twitter Profile
Ahmed Aly

@a_aly_hussein

Urologist at Cairo University and Roswell Park Comprehensive Cancer Center. Views are my own

ID: 4071476248

calendar_today30-10-2015 00:18:02

1,1K Tweet

327 Followers

197 Following

Olivier Traxer (@otraxer) 's Twitter Profile Photo

T&TV59: A very important movement when “painting” the surface of stone for excellent dusting. 1st : Keep the perfect distance between stone’s surface & Laser Fiber (never touch it) & 2nd: ROTATE the scope with your left thumb & index finger (reproducing minimal torque mvt)

Patrick Hensley, MD (@pjhensley11) 's Twitter Profile Photo

Progression on BCG to MIBC managed without NAC portends poor prognosis after RC. Treating these patients with contemporary NAC achieves similar survival as de novo BCa patients. Pres. this pm session PD51 #aua2021 Ashish M. Kamat, MD, MBBS Kelly Bree MD Anderson Cancer Center Eugene Lee

Progression on BCG to MIBC managed without NAC portends poor prognosis after RC. Treating these patients with contemporary NAC achieves similar survival as de novo BCa patients. Pres. this pm session PD51 #aua2021 <a href="/UroDocAsh/">Ashish M. Kamat, MD, MBBS</a> <a href="/KKBree/">Kelly Bree</a> <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/eugenekanglee/">Eugene Lee</a>
European Urology (@euplatinum) 's Twitter Profile Photo

2021 Best Scientific Paper on Clinical Research Treatment of High-grade NMIBC by Standard Number and Dose of BCG Instillations Vs Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology (EAU) Research Foundation Phase 3 RCT “NIMBUS” buff.ly/2ZJLzH5

2021 Best Scientific Paper on Clinical Research

Treatment of High-grade NMIBC by Standard Number and Dose of BCG Instillations Vs Reduced Number and Standard Dose of BCG Instillations: Results of the <a href="/Uroweb/">European Association of Urology (EAU)</a> Research Foundation Phase 3 RCT “NIMBUS”

buff.ly/2ZJLzH5
Jelle Barentsz (@jellebarentsz) 's Twitter Profile Photo

PI-RR (Prostate Magnetic Resonance Imaging for Local Recurrence Reporting) is the ‘PI-RADS’ assessment for prostate cancer recurrence after wholke gland therapy (prostatectomy or radiotherapy). see: DOI: 10.1016/j.euo.2021.01.003

Mary Beth Westerman (@drmbwesterman) 's Twitter Profile Photo

Great technique for preventing lymphoceles after Plnd by Daniel D Eun MD Temple Urology Peritoneal interposition flaps - no lymphoceles in multiple studies! #NARUS2022 @NAmerRoboUrol

Great technique for preventing lymphoceles after Plnd by <a href="/md_eun/">Daniel D Eun MD</a> <a href="/TempleUrology/">Temple Urology</a> 

Peritoneal interposition flaps - no lymphoceles in multiple studies!

#NARUS2022 @NAmerRoboUrol
Baris Turkbey MD (@radiolobt) 's Twitter Profile Photo

Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer pubs.rsna.org/doi/10.1148/rg… 🔵A must read article for clinicians who are interested in localized #prostatecancer 👍Congrats to all Authors #CancerResearch #MedTwitter

Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer pubs.rsna.org/doi/10.1148/rg… 
🔵A must read article for clinicians who are interested in localized #prostatecancer 
👍Congrats to all Authors 
#CancerResearch #MedTwitter
Abraham Morgentaler, MD (@drmorgentaler) 's Twitter Profile Photo

Can’t tweet about this study enough! TTh reduced DM rates. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial - PubMed pubmed.ncbi.nlm.nih.gov/33338415/

Jelle Barentsz (@jellebarentsz) 's Twitter Profile Photo

doi.org/10.1016/j.euro…. - Expert-EAU group made enormous efforts for algorithm optimizing benefits vs harms in early PCa detection - Pre-MRI Risk Calculator avoids 41% of MRIs and 60% of biopsies at a cost of missing 5% csPCa - PSAD>.10 avoids 34% of MRI at a cost of 4% csPCa

doi.org/10.1016/j.euro….

- Expert-EAU group made enormous efforts for algorithm optimizing benefits vs harms in early PCa detection

- Pre-MRI Risk Calculator avoids 41% of MRIs and 60% of biopsies at a cost of missing 5% csPCa

- PSAD&gt;.10 avoids 34% of MRI at a cost of 4% csPCa
European Urology (@euplatinum) 's Twitter Profile Photo

Predicting the Need for Biopsy to Detect csPCa in Pts with MRI–detected PIRADS/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score buff.ly/3PmIuCE Peters, Hashim U. Ahmed et al

Predicting the Need for Biopsy to Detect csPCa in Pts with MRI–detected PIRADS/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score buff.ly/3PmIuCE 

Peters, <a href="/LondonProstate1/">Hashim U. Ahmed</a>  et al
Marcelo Wroclawski (@wroclawski_uro) 's Twitter Profile Photo

Is MRI a game-changer to properly investigate urethral stenosis and plan the appropriate treatment? Or retrograde urethrography is enough? #UroSoMe

Is MRI a game-changer to properly investigate urethral stenosis and plan the appropriate treatment? Or retrograde urethrography is enough?
#UroSoMe
Jelle Barentsz (@jellebarentsz) 's Twitter Profile Photo

This strongly supports risk adapted early detection/screening: - PSA (when >3 ng/ml) followed by - risk calculator, when positive followed by - bi-parametric (quality controlled) MRI and MR-targeted biopsy.

Baris Turkbey MD (@radiolobt) 's Twitter Profile Photo

Very nice analysis of Targeted Biopsy negative Prostate Lesions using #prostateMRI 🇬🇧🇫🇷🇺🇸 "Magnetic Resonance Imaging Follow-up of Targeted Biopsy-negative Prostate Lesions" sciencedirect.com/science/articl… #cancerresearch #medtwitter #teamscience

Very nice analysis of Targeted Biopsy negative Prostate Lesions using #prostateMRI 🇬🇧🇫🇷🇺🇸 
"Magnetic Resonance Imaging Follow-up of Targeted Biopsy-negative Prostate Lesions" sciencedirect.com/science/articl…
#cancerresearch #medtwitter #teamscience
Jelle Barentsz (@jellebarentsz) 's Twitter Profile Photo

Why NOT call GS 3+3 benign: 1. 3+3 has same microsc., immunohistochem. & molecular features as >3+3 2. 3+3 can show pT3 & metas 3. 3+3 is often undergraded and undersampled 4. Due to interobserver variability 3+3 can turn into 3+4. This is difficult to explain to patient

Firas Abdollah (@drfabdollah) 's Twitter Profile Photo

1/2 I can’t help but feel that the reply from authors confirm our concerns about the generalizability of the Protect trial: 1) Protect represent community-based screening, which doesn’t happen in US practice, NEJM pubmed.ncbi.nlm.nih.gov/37407012/